Rocket Pharmaceuticals Inc. (RCKT) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, RCKT scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 3/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 7/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is the cash engine, consistent with the reported ROIC of -35% and zero FCF yield. For a prospective investor, the rating signals that the business is not currently generating cash returns on its capital, and the forensic metrics point to elevated balance-sheet risk. Any upside case would have to rest on events outside the reported cash-generation profile, since the rating assigns the lowest weight to near-term cash fundamentals. Valuation tradeoffs are difficult to frame because earnings-based multiples are not available in source data, so the stock cannot be benchmarked on P/E or EV/EBITDA from these sources.

Per the SEC financials, operating and net losses persist across all three reported periods, with gross, operating, and net margins each at 0%. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $163.6M in FY 2024 to $77.6M in FY 2025, while FCF remained negative in each period, so the source data indicates ongoing cash consumption rather than self-funding.

The news wire contains six items tied to RCKT. A RED-flagged "RISK WATCH" item reports that Jefferies cut the stock's price target on timeline. A YELLOW "MARKET WIRE" item reports a strategic credit facility for up to $150 Million from Hercules Capital. A YELLOW item reports that five of six patients showed lower heart muscle measurements about 3 to 7 years after gene therapy. A GREEN "CATALYST" item reports that Leerink Partners maintains a Market Perform rating with a $4 price target. A YELLOW item reports that Cantor Fitzgerald reiterated its rating. A GREEN "CATALYST" item reports shares rising after a Goldman Sachs upgrade. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What is the drawn amount, covenant structure, and repayment schedule of the Hercules Capital facility?
• What are the clinical and regulatory milestones underlying the Jefferies price-target change and the Leerink and Goldman Sachs ratings?
• What is the company's revenue model and does any product generate commercial sales?
• What is the remaining cash runway at the current FCF burn rate, and what financing is planned?
• What are the details of the heart-muscle measurement data and its implications for the program?